Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$190.53 +2.2%	$186.95	$163.81 ▼ $218.66	$329.24B	0.48	6.33 million shs	6.20 million shs
HSP Hospira		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$164.78 +6.2%	$153.95	$140.68 ▼ $169.99	$373.35B	0.41	8.15 million shs	22.13 million shs
LLY Eli Lilly and Company	$788.91 +2.2%	$766.12	$677.09 ▼ $972.53	$731.42B	0.4	3.68 million shs	3.25 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+2.13%	-0.11%	-0.20%	+10.28%	+12.61%
JNJ Johnson & Johnson	+6.05%	+5.58%	+6.14%	+4.67%	+9.12%
LLY Eli Lilly and Company	+2.09%	+0.24%	-2.32%	-6.27%	-16.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.8383 of 5 stars	3.4	3.0	4.2	3.9	3.2	1.7	1.3
HSP Hospira	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	4.7757 of 5 stars	2.3	4.0	4.2	3.9	3.4	1.7	1.9
LLY Eli Lilly and Company	4.9768 of 5 stars	4.4	4.0	3.3	4.0	2.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	10.89% Upside
HSP Hospira	0.00	N/A	N/A	N/A
JNJ Johnson & Johnson	2.55	Moderate Buy	$171.00	3.77% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,012.56	28.35% Upside

Current Analyst Ratings Breakdown

Latest HSP, LLY, JNJ, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$936.00 ➝ $942.00
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
7/10/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$1,133.00 ➝ $1,135.00
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$169.00 ➝ $171.00
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.97	$15.27 per share	12.48	$1.90 per share	100.28
HSP Hospira	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$88.82B	4.46	$13.93 per share	11.83	$29.69 per share	5.55
LLY Eli Lilly and Company	$45.04B	16.60	$14.55 per share	54.22	$15.03 per share	52.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	81.08	13.63	1.24	7.31%	412.03%	13.11%	7/31/2025 (Estimated)
HSP Hospira	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$14.07B	$8.99	18.33	14.89	2.12	24.42%	33.46%	13.30%	N/A
LLY Eli Lilly and Company	$10.59B	$12.29	64.19	25.35	1.12	22.67%	85.51%	15.74%	8/7/2025 (Estimated)

Latest HSP, LLY, JNJ, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.56	N/A	N/A	N/A	$14.40 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.44%	N/A	279.15%	53 Years
HSP Hospira	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.16%	N/A	57.84%	64 Years
LLY Eli Lilly and Company	$6.00	0.76%	N/A	48.82%	11 Years

Latest HSP, LLY, JNJ, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%		8/26/2025	9/9/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
HSP Hospira	N/A	N/A	N/A
JNJ Johnson & Johnson	0.49	1.26	1.03
LLY Eli Lilly and Company	2.18	1.37	1.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
HSP Hospira	N/A
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
HSP Hospira	N/A
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
HSP Hospira	N/A	N/A	N/A	Not Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable

HSP, LLY, JNJ, and ABBV Headlines

Recent News About These Companies

Lilly’s Zepbound faces a potential weight-loss rival. It’s made by a Chinese biotech

July 16 at 9:47 PM | livemint.com

Eli Lilly’s Stock (LLY) Is a ‘Coiled Spring,’ Says Jim Cramer

July 16 at 2:58 PM | tipranks.com

Pharmaceutical Stocks To Consider - July 16th

July 16 at 2:41 PM | marketbeat.com

Eli Lilly and Company (NYSE:LLY) Trading 3% Higher - Time to Buy?

July 16 at 1:29 PM | marketbeat.com

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound

July 16 at 1:19 PM | cnbc.com

Trust Investment Advisors Boosts Position in Eli Lilly and Company (NYSE:LLY)

July 16 at 9:59 AM | marketbeat.com

Welch & Forbes LLC Has $122.68 Million Stake in Eli Lilly and Company (NYSE:LLY)

July 16 at 8:43 AM | marketbeat.com

Altman Advisors Inc. Buys 1,046 Shares of Eli Lilly and Company (NYSE:LLY)

July 16 at 8:42 AM | marketbeat.com

Cullen Frost Bankers Inc. Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

July 16 at 8:14 AM | marketbeat.com

Bipartisan support helps foundations avoid tax increase in new Trump legislation

...

July 16 at 8:03 AM | marketbeat.com

Eli Lilly and Company (NYSE:LLY) Shares Sold by Victory Capital Management Inc.

July 16 at 7:31 AM | marketbeat.com

Prevail Innovative Wealth Advisors LLC Sells 4,326 Shares of Eli Lilly and Company (NYSE:LLY)

July 16 at 6:09 AM | marketbeat.com

Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?”

July 16 at 2:28 AM | insidermonkey.com

Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?”

July 16 at 2:27 AM | msn.com

Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS

July 15 at 8:20 PM | msn.com

Eli Lilly Foundation awards $5.5M grant to IPS Foundation for STEM

July 15 at 8:20 PM | indianapolisrecorder.comI

Top Research Reports for Eli Lilly, Netflix & GE Aerospace

July 15 at 8:20 PM | finance.yahoo.com

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (LLY)

...

July 15 at 4:27 PM | marketbeat.com

Eli Lilly’s Weight-Loss Drug Faces New Competition from China

July 15 at 3:45 PM | tipranks.com

Top Pharmaceutical Stocks To Keep An Eye On - July 15th

July 15 at 3:35 PM | marketbeat.com

Eli Lilly and Company (NYSE:LLY) Trading Down 3.4% - Here's Why

July 15 at 3:21 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
3 Stocks With Near-Unanimous Buys That Could Rally Higher
By Nathan Reiff | July 2, 2025
View 3 Stocks With Near-Unanimous Buys That Could Rally Higher
3 Notable Stocks Just Split: Which One Could Be the Big Winner?
By Leo Miller | June 26, 2025
View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?

HSP, LLY, JNJ, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$190.53 +4.14 (+2.22%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$190.20 -0.33 (-0.17%)

As of 07/16/2025 07:41 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Hospira NYSE:HSP

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.

Johnson & Johnson NYSE:JNJ

$164.78 +9.61 (+6.19%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$164.28 -0.50 (-0.30%)

As of 07/16/2025 08:00 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$788.91 +17.16 (+2.22%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$788.05 -0.86 (-0.11%)

As of 07/16/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time